Cancer is one of the main public health problems in developed and developing countries. According to the World Health Organization, 21 million new cases of cancer and 11.5 million deaths from cancer will occur annually around the world by 2030 (
12). Renal cell carcinoma is one of the most common cancers, especially in developed countries. They are tumors that originate from epithelial cells of the renal tubules and account for over 90% of kidney tumors. Renal cell carcinoma is the eighth malignancy among the most common cancers in America (
13). The induction of apoptosis or programmed cell death is characterized by certain features such as chromatin condensation, DNA fragmentation, membrane buckling, caspase activity, and phosphatidylserine transfer from the inner to outer layers of the plasma membrane, which is one of the useful tools for cancer treatment (
14).
Chemotherapeutic drugs can induce apoptosis, often due to DNA damage and oxidative stress. Oxidative stress is a condition in which the imbalance comes from the production of free radicals and antioxidant defense systems (
15). Among chemotherapeutic drugs, it will be beneficial to use compounds that act with the oxidative stress system inside the cancerous cell, such as flavonoid family derivatives. In addition, many studies have indicated that some of these flavonoids have specific applications, especially for the treatment of certain cancers. Many of these compounds can also be effective in overall cancer treatment processes through the mechanisms of inhibiting DNA synthesis, modifying ROS production, regulating the cell cycle, and repairing apoptotic pathways (
16). Flavonoids are known as potent antioxidants that protect cells from oxygen-derived free radicals (
16). They prevent mutations and initiate carcinogenesis. Recently, it has been observed that they can induce apoptosis in cancerous cells (
17). Therefore, further studies are needed to identify the molecular mechanism of naturally occurring anticancer compounds, especially plant-derived compounds.
Evidence suggests that ferulic acid can act as an antitumor agent in various human cancers. It has been shown that ferulic acid inhibits 7,12-Dimethylbenz [a] anthracene-induced (DMBA) in breast and skin cancers through anti-genotoxic and antioxidant features, regulating the effects in phase II detoxification cascades and reducing buccal cancer through decreasing the expression of PCNA and Cyclin D1 (
18). In addition, it has been reported that ferulic acid, curcumin, chlorogenic acid, and caffeic acid can inhibit skin cancer induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in rats (
19). Ferulic acid is expected to reduce ROS (
11); however, since the cancerous cell has an acidic region (
20), ferulic acid is unable to play a role as an antioxidant but acts mostly as a pro-oxidant (
21). Studies show that ferulic acid, along with radiotherapy, can reduce the antioxidant status and increase ROS, lipid peroxidation, and DNA damage (
21). One of the reasons for increasing ROS by ferulic acid may be attributed to its effect on P53 activity. Ferulic acid has been reported to inhibit the change in the function of P53 in buccal carcinoma and has a beneficial effect in treating this type of cancer (
22). As known, P53 is a tumor suppressor (
23), which also plays a role in regulating the expression of many pro-oxidant and antioxidant genes, including catalase, superoxide dismutase, and glutathione peroxidase. Increasing its proper functioning can lead to a loss of redox hemostasis (
24) and induce oxidative stress (
25).
The results of this study indicated that ferulic acid can prevent renal carcinoma cell line proliferation in a concentration-dependent manner. Ferulic acid has been reported to induce apoptosis in non-small cell lung cancer (NSCLC) by increasing P53, Bax, caspase 3, and GADD45 (
26), as well as in the Caco-2 colon cancer cell line, causing a delay in the synthesis phase of the cell cycle and an increase in the expression of CEP2, CETN3, and RABGAP1 genes, which control DNA damage in the cell cycle of the S phase (
27). In the present study, it was found that the anticancer effect and apoptotic induction property of ferulic acid can be due to an increase in the expression of the Bax gene and a decrease in the expression of the Bcl-2 gene, which encodes the apoptotic proteins. It has been proven that ferulic acid induces apoptosis through increasing the expression of the Bax and caspase 3 genes and decreasing the expression of the Bcl-2 gene (
28).
The safety of ferulic acid should be considered because ferulic acid has a nephrodamaging effect in chronic use (
29). It has also been demonstrated that ferulic acid can reduce multi-drug resistance (MDR) to paclitaxel in cancer cell line KB. This effect is induced by decreasing the expression of the ABCB1 and p-glycoprotein genes, inducing apoptosis through increasing the P53 expression, increasing the Bax/Bcl-2 expression ratio, and increasing CDKN1A, ultimately leading to the enhancement of cell cycle arrest in the G2/M phase along with paclitaxel (
30). Besides, Bcl-2 is the first known gene associated with apoptosis, which plays a role in tumor formation (
31). The members of the Bcl-2 family in mammals can control the internal pathway of apoptosis by inhibiting the release of cytochrome C and other mitochondrial membrane proteins into cytosol. Some members of the Bcl-2 family, including Bax, act as pro-apoptotic agents and proceed to apoptosis by increasing the release of mitochondrial proteins. However, some other members, such as Bcl-2, act as anti-apoptotic factors and cause the inhibitory release of mitochondrial proteins. Indeed, these two groups restrain each other's actions. The balance between their activities usually determines the presence or absence of cell apoptotic induction (
31).
In the current study, the treatment of cancer cells with different concentrations of ferulic acid resulted in cell apoptosis as confirmed by flow cytometry. The flow cytometry studies with Annexin V staining in ferulic acid-treated cells indicated the apoptosis and introduction into the apoptotic phase compared to the control group (without ferulic acid treatment). It was also shown that apoptosis is a major cause of cell death and growth inhibition in predicted concentrations. However, a very small percentage of cells had necrosis, but this rate was not significant compared to the percentage of apoptotic cells. The findings of this study revealed that ferulic acid can precede renal carcinoma cells towards apoptosis and prevent their proliferation.
5.1. Conclusion
According to the results obtained in the present study, ferulic acid has apoptotic effects against ACHN cancer cells. These findings can be helpful in the better understanding of ferulic acid anticancer mechanisms, suggesting its use as an alternative or complementary drug for cancer therapy.